When to Use Initial Triple Therapy in COPD: Adding a LAMA to ICS/LABA by Clinically Important Deterioration Assessment.
Wen-Chien ChengBiing-Ru WuWei-Chih LiaoChih-Yu ChenWei-Chun ChenTe-Chun HsiaChih-Yen TuChia-Hung ChenWu-Huei HsuPublished in: International journal of chronic obstructive pulmonary disease (2020)
Triple therapy (ICS/LABAs/LAMAs) may be considered as first-line treatment in patients experiencing more than 2 times moderate to severe AEs of COPD in the previous year and who have blood eosinophil counts ≥100 cells/μL, reduced lung function (FEV1 ≤ 42%), and more symptoms (CAT score ≥ 18).